CAPR Stock Has Retail’s Attention After SLS Rally — But 2 Other Drugs Could Have Better Estimated FDA Approval Odds This Month
Estimated approval odds are 62% for Capricor’s therapy, 85% for Savara’s drug facing the same Sunday target date, and 79% for Sanofi’s drug awaiting a Nov.25 decision.